tiprankstipranks
Trending News
More News >
Guard Therapeutics International AB (SE:GUARD)
:GUARD

Guard Therapeutics International AB (GUARD) AI Stock Analysis

Compare
0 Followers

Top Page

SE

Guard Therapeutics International AB

(Frankfurt:GUARD)

Rating:32Underperform
Price Target:
Guard Therapeutics International AB faces challenges typical of early-stage biotechnology companies, such as zero revenue and significant R&D expenses leading to ongoing losses. Despite a strong equity position with no debt, the financial health is concerning if the company fails to commercialize its research outcomes. The technical indicators suggest the stock is oversold, which may offer short-term trading opportunities. However, the negative P/E ratio and lack of dividends highlight valuation concerns typical for firms in this stage.

Guard Therapeutics International AB (GUARD) vs. iShares MSCI Sweden ETF (EWD)

Guard Therapeutics International AB Business Overview & Revenue Model

Company DescriptionGuard Therapeutics International AB (publ), a pharmaceutical company, identifies, develops, and commercializes therapies for the diagnosis and treatment of acute kidney injuries in Sweden. It offers ROSGard, a biological drug candidate that prevents kidney damage by protecting, cleaning, and repairing the exposed cells and tissues. The company was formerly known as A1M Pharma AB (publ) and changed its name to Guard Therapeutics International AB (publ) in October 2019. Guard Therapeutics International AB (publ) was incorporated in 2008 and is based in Stockholm, Sweden.
How the Company Makes MoneyGuard Therapeutics primarily makes money through the development and potential commercialization of its drug candidate, ROSgard. Revenue streams include potential milestone payments, royalties, and licensing agreements with pharmaceutical companies upon successful regulatory approval and commercialization. The company may also receive funding through research grants, partnerships, and collaborations with other biotech firms or research institutions. Significant factors contributing to its earnings include the successful advancement of ROSgard through clinical trials and securing strategic partnerships for distribution and marketing.

Guard Therapeutics International AB Financial Statement Overview

Summary
Guard Therapeutics International AB is in a typical early-stage biotechnology phase, marked by zero revenue, substantial R&D investments, and reliance on external financing to sustain operations. While the company has no debt and a strong cash position, the continuous net losses and negative cash flows pose risks if they persist without revenue growth.
Income Statement
15
Very Negative
Guard Therapeutics International AB has consistently reported zero revenue over the years, reflecting the early-stage nature typical of biotechnology firms. The company is experiencing significant net losses, which have gradually increased over time, indicating ongoing investment in research and development without corresponding revenue generation. Both EBIT and EBITDA margins are negative, further highlighting operational losses.
Balance Sheet
40
Negative
The company maintains a strong equity position with no debt, which is a positive aspect for financial stability. However, the equity has been declining over the years due to continued losses. The absence of revenue generation poses a risk to maintaining this balance in the long term, despite the current lack of leverage.
Cash Flow
25
Negative
Guard Therapeutics shows negative operating cash flow, consistent with its early-stage biotech status. While free cash flow is negative, there have been significant financing inflows, especially in the earlier years, which have helped sustain operations. However, the trend of increasing cash burn is concerning if not matched by future revenue generation.
Breakdown
Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.00
Gross Profit
0.00-15.00K-15.00K-15.00K-161.00K
EBIT
-99.91M-115.07M-114.92M-81.90M-40.28M
EBITDA
-100.23M-114.91M-112.82M-82.01M-40.12M
Net Income Common Stockholders
-96.07M-113.32M-110.76M-82.16M-40.29M
Balance SheetCash, Cash Equivalents and Short-Term Investments
54.19M83.74M201.01M188.60M90.04M
Total Assets
55.74M85.23M202.60M190.44M91.22M
Total Debt
0.000.000.000.000.00
Net Debt
-54.19M-83.74M-201.01M-188.60M-90.04M
Total Liabilities
17.77M18.49M25.24M14.66M11.54M
Stockholders Equity
37.97M66.73M177.36M175.78M79.69M
Cash FlowFree Cash Flow
-94.75M-116.05M-102.14M-77.59M-37.96M
Operating Cash Flow
-94.75M-116.05M-102.14M-77.59M-37.96M
Investing Cash Flow
0.000.00-1.00K0.00118.00K
Financing Cash Flow
62.66M-779.00K112.60M176.30M74.05M

Guard Therapeutics International AB Technical Analysis

Technical Analysis Sentiment
Positive
Last Price18.60
Price Trends
50DMA
14.64
Positive
100DMA
17.83
Positive
200DMA
20.45
Negative
Market Momentum
MACD
1.14
Negative
RSI
68.95
Neutral
STOCH
69.06
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:GUARD, the sentiment is Positive. The current price of 18.6 is above the 20-day moving average (MA) of 16.05, above the 50-day MA of 14.64, and below the 200-day MA of 20.45, indicating a neutral trend. The MACD of 1.14 indicates Negative momentum. The RSI at 68.95 is Neutral, neither overbought nor oversold. The STOCH value of 69.06 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SE:GUARD.

Guard Therapeutics International AB Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.28-45.10%2.80%16.76%0.02%
48
Neutral
kr379.37M-47.73%45.52%93.35%
44
Neutral
€267.41M-18.79%21.85%
42
Neutral
€367.40M-24.61%47.06%33.86%
40
Underperform
kr321.97M
1.72%32.54%
32
Underperform
kr375.12M-205.65%24.25%
31
Underperform
€289.38M-167.55%46.67%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SE:GUARD
Guard Therapeutics International AB
18.60
-15.54
-45.52%
SE:ONCO
Oncopeptides AB
1.52
-1.85
-54.90%
SE:CANTA
Cantargia AB
1.16
-3.43
-74.66%
SE:IMMU
Immunicum AB
5.31
-4.28
-44.63%
SE:IVACC
Intervacc AB
1.08
-1.79
-62.37%
SE:XBRANE
Xbrane Biopharma AB
0.25
-0.06
-19.81%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.